(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) slid by a staggering 30.7% in 21 sessions from $22.28 at 2023-06-02, to $15.44 at 15:00 EST on Monday, after four consecutive sessions in a row of gains. NASDAQ is rising 0.21% to $13,816.77, following the last session’s upward trend.
Viking Therapeutics’s last close was $16.21, 36.98% below its 52-week high of $25.72.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.77.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.
Moving Average
Viking Therapeutics’s value is way below its 50-day moving average of $21.61 and way higher than its 200-day moving average of $11.29.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.75%, a negative 1.52%, and a positive 3.65%.
Viking Therapeutics’s highest amplitude of average volatility was 7.15% (last week), 4.49% (last month), and 3.65% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Viking Therapeutics’s EBITDA is -56.81.
More news about Viking Therapeutics (VKTX).
